{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166264881",
    "name" : "Annotation of DPWG Guideline for phenytoin and HLA-B",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : false,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1451695782,
        "date" : "2022-02-25T00:00:00-08:00",
        "type" : "Create",
        "version" : 1
      },
      {
        "id" : 1451704256,
        "date" : "2022-03-03T16:33:35.593-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451706360,
        "date" : "2022-03-07T16:57:41.122-08:00",
        "description" : "Added information about preemptive genotyping",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451732896,
        "date" : "2022-03-28T09:57:49.538-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451733444,
        "date" : "2022-03-28T15:00:28.025-07:00",
        "description" : "Updated link to testing guidance page",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451741459,
        "date" : "2022-04-05T11:17:45.353-07:00",
        "description" : "Added testing guidance tag",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451884506,
        "date" : "2022-09-16T11:06:42.137-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146468,
        "date" : "2023-07-03T13:39:53.585-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452412520,
        "date" : "2024-03-19T05:44:00.190-07:00",
        "description" : "Updated links for risk analysis pdf and preemptive testing page.",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [],
    "otherPrescribingGuidance" : true,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Haplotype",
        "id" : "PA165954769",
        "symbol" : "HLA-B*15:02",
        "name" : "*15:02",
        "version" : 5
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA450947",
        "name" : "phenytoin",
        "version" : 14
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA35056",
        "symbol" : "HLA-B",
        "name" : "major histocompatibility complex, class I, B",
        "version" : 40
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1451695780,
      "html" : "<p>Phenytoin should be avoided if possible in patients with the HLA-B*15:02 allele.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451695781,
      "html" : "<p>Read more about how PharmGKB <a href=\"/page/dpwgMapping\">curates DPWG guidelines</a> using extra information provided by DPWG to enable the interactive genotype tool above.</p>\n<h3 id=\"may-2021\">May 2021</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenytoin based on HLA-B*15:02.</p>\n<p>The annotation of the DPWG guideline for phenytoin and CYP2C9 can be found <a href=\"/guidelineAnnotation/PA166104984\">here</a></p>\n<p><em>Wording in table taken from the <a download=\"DPWG_May_2021.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_May_2021.pdf\">Dutch guidelines May 2021 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>HLA-B*1502</td>\n<td>phenytoin</td>\n<td>The life-threatening cutaneous side effect Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) occurs more frequently in patients with this genetic variation. The calculated risk of phenytoin-induced SJS/TEN in patients with HLA-B*1502 is 0.65%.</td>\n<td>Carefully weigh the risk of SJS/TEN against the benefits.<br/>Avoid phenytoin if an alternative is possible. Carbamazepine carries a 10-fold higher risk of SJS/TEN for these patients and is therefore not an alternative. A comparable risk has been reported for lamotrigine as for phenytoin. The same applies for oxcarbazepine, but the most severe forms (SJS/TEN overlap and TEN) are not observed with oxcarbazepine.<br/>If it is not possible to avoid this medication, then advise the patient to report any skin rash immediately</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_HLA_phenytoin_6927.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_HLA_phenytoin_6927.pdf\">Read for more information about this recommendation</a>, <a download=\"HLAs.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/HLAs.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_HLA_phenytoin_6927.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_HLA_phenytoin_6927.pdf\">DPWG risk analysis document</a> for phenytoin and HLA:</p>\n<blockquote class=\"blockquote\">\n<p>HLA-B*1502 has not been detected in a sample of 1350 Dutch persons (Allele Frequency Net Database: http://www.allelefrequencies.net). For this reason, the Dutch Pharmacogenetics Working Group does not consider genotyping of Dutch patients in general before starting phenytoin to be useful.\nHowever, the HLA-B*1502 frequency is high in Asians, except for Japanese and Koreans. The Dutch Pharmacogenetics Working Group considers genotyping of patients of Asian descent other than Japanese or Korean descent before starting phenytoin to be beneficial for drug safety. It is advised to genotype these patients before (or directly after) drug therapy has been initiated to guide drug and dose selection.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n",
      "version" : 5
    },
    "version" : 9
  }
}